Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22713231 | 1.00 | CTSD (0.33) | CTSDBACE1S1PR1S1PR3 | |
| SCHEMBL29504040 | 1.00 | CTSD (0.33) | CTSDBACE1S1PR1S1PR3 | |
| SCHEMBL22713228 | 1.00 | CTSD (0.33) | CTSDBACE1S1PR1S1PR3 | |
| SCHEMBL25374985 | 0.83 | S1PR4 (0.30) | S1PR3 | |
| SCHEMBL18425740 | 0.83 | S1PR4 (0.30) | S1PR3 | |
| SCHEMBL25374979 | 0.83 | S1PR4 (0.30) | S1PR3 | |
| SCHEMBL30204984 | 0.83 | S1PR4 (0.30) | S1PR3 | |
| SCHEMBL29698709 | 0.83 | S1PR4 (0.30) | S1PR3 | |
| SCHEMBL20758632 | 0.81 | B3GNT2 (0.36) | CTSDBACE1S1PR1S1PR3 | |
| SCHEMBL20758639 | 0.81 | B3GNT2 (0.36) | CTSDBACE1S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486281-B2 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| CN-114957212-A | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | 细胞基因公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220213115-A1 | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2022-07-07 | — | — | US | disclosed |
| US-11306101-B2 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2022-04-19 | — | — | US | disclosed |
| CN-114269729-A | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | 细胞基因公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20200377512-A1 | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377512-A1 | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CPT1A, GOT2, IDH2 | CTSD 2161/4885BACE1 640/4885S1PR1 3147/4885 |
| US-20220213115-A1 | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CPT1A, GOT2, IDH2 | CTSD 2161/4885BACE1 640/4885S1PR1 3147/4885 |
| US-11306101-B2 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | CPT1A, GOT2, IDH2 | CTSD 2161/4885BACE1 640/4885S1PR1 3147/4885 |
| US-12486281-B2 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | CPT1A, GOT2, IDH2 | CTSD 2161/4885BACE1 640/4885S1PR1 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.